SCHEDULE 13G/A: Perceptive Advisors and Affiliates Divest Entire Stake in Acrivon Therapeutics, Filing Amended 13G
Ownership Disclosure
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a complete divestment of their beneficial ownership in Acrivon Therapeutics, Inc., holding 0.0% of common stock as of June 2, 2025.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 5 to Schedule 13G regarding their holdings in Acrivon Therapeutics, Inc.
- As of the event date of June 2, 2025, the Reporting Persons beneficially own 0.00 shares of Acrivon Therapeutics, Inc. Common Stock, representing 0.0% of the class.
- This filing indicates a complete divestment of their previous holdings, as all beneficial ownership, voting power, and dispositive power are reported as zero.
- Perceptive Advisors LLC serves as the investment manager to Perceptive Life Sciences Master Fund, Ltd., and Joseph Edelman is the managing member of Perceptive Advisors LLC.
Sentiment
Score: 3
Explanation: The sentiment is negative because a prominent institutional investor, Perceptive Advisors and its affiliates, has fully divested its stake in Acrivon Therapeutics, Inc., which can be interpreted as a loss of confidence or a strategic exit from the investment.
Negatives
- The complete divestment of shares by Perceptive Advisors and its affiliates, prominent institutional investors, could be perceived negatively by the market as it suggests a lack of confidence or a strategic shift away from Acrivon Therapeutics, Inc.
Future Outlook
NA
Industry Context
This filing reflects a change in an institutional investor's position within the biotechnology or pharmaceutical sector, specifically regarding Acrivon Therapeutics, Inc. While not directly indicative of broader industry trends, significant divestments by specialized life sciences funds like Perceptive can sometimes signal shifts in investment strategy or outlook concerning specific companies or sub-sectors.
Stakeholder Impact
- Shareholders: The divestment by a significant institutional investor could lead to negative market sentiment and potentially impact the company's share price, especially if other investors follow suit or interpret it as a negative signal about the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 06/02/2025 | Date of event which requires the filing of this statement, indicating the effective date of the reported ownership change. |
| 06/04/2025 | Date the Schedule 13G Amendment No. 5 was signed by Joseph Edelman on behalf of all Reporting Persons. |
Keywords
Acrivon Therapeutics, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Schedule 13G, SEC filing, beneficial ownership, stock divestment, institutional investor, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.